Inactive Instrument

Highlights PHOX BIOT26 Nasdaq

Equities

PBAXU

US71902K2042

Highlights

Unlock all the news: Be the first to know and act before the market!

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236	06-06	CI
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-17	CI
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-02	CI
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients	03-07	CI
Phoenix Biotech Acquisition Completes Merger With CERo Therapeutics	02-15	MT
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc.	02-13	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Phoenix Biotech Acquisition Corp. executed the letter of intent to acquire CERo Therapeutics, Inc. for $86.9 million.	04/06/23	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	24/03/23	CI
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	24/03/23	CI
PHOENIX BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	24/03/23	AQ
PHOENIX BIOTECH ACQUISITION CORP. : Other Events (form 8-K)	27/01/23	AQ
PHOENIX BIOTECH ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	20/12/22	AQ
Phoenix Biotech Acquisition Corp. cancelled the acquisition of Intrinsic Medicine, Inc. from Phoenix Biotech Sponsor, LLC, Beryl Capital Management LLC, Highbridge Capital Management, LLC, Saba Capital Management, L.P. and others.	05/12/22	CI
PHOENIX BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	10/11/22	AQ
Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Phoenix Biotech to Take Intrinsic Medicine Public in SPAC Deal	31/10/22	MT
PHOENIX BIOTECH ACQUISITION CORP. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	31/10/22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PHOX BIOT26 Nasdaq

Equities

PBAXU

US71902K2042

Highlights

Filters